[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2007133803A3 - Treatment of mycobacterial infections - Google Patents

Treatment of mycobacterial infections Download PDF

Info

Publication number
WO2007133803A3
WO2007133803A3 PCT/US2007/011722 US2007011722W WO2007133803A3 WO 2007133803 A3 WO2007133803 A3 WO 2007133803A3 US 2007011722 W US2007011722 W US 2007011722W WO 2007133803 A3 WO2007133803 A3 WO 2007133803A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
mycobacterial infections
mediated
mycobacteria
infections caused
Prior art date
Application number
PCT/US2007/011722
Other languages
French (fr)
Other versions
WO2007133803A2 (en
Inventor
Joyce A Sutcliffe
Original Assignee
Rib X Pharmaceuticals Inc
Joyce A Sutcliffe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rib X Pharmaceuticals Inc, Joyce A Sutcliffe filed Critical Rib X Pharmaceuticals Inc
Publication of WO2007133803A2 publication Critical patent/WO2007133803A2/en
Publication of WO2007133803A3 publication Critical patent/WO2007133803A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to methods for treating, reducing the risk of, and preventing mycobacterial infections, for example infections caused or mediated by Mycobacterium tuberculosis or nontuberculosis mycobacteria and in particular those infections caused or mediated by resistant or highly virulent strains of mycobacteria, using a safe and effective amount of an antibiotic compound.
PCT/US2007/011722 2006-05-15 2007-05-15 Treatment of mycobacterial infections WO2007133803A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80077806P 2006-05-15 2006-05-15
US60/800,778 2006-05-15
US89909507P 2007-02-01 2007-02-01
US60/899,095 2007-02-01

Publications (2)

Publication Number Publication Date
WO2007133803A2 WO2007133803A2 (en) 2007-11-22
WO2007133803A3 true WO2007133803A3 (en) 2008-01-10

Family

ID=38578556

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/011722 WO2007133803A2 (en) 2006-05-15 2007-05-15 Treatment of mycobacterial infections

Country Status (1)

Country Link
WO (1) WO2007133803A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3095445A1 (en) * 2009-10-13 2016-11-23 Melinta Therapeutics, Inc. Pharmaceutical compositions comprising radezolid
WO2011139832A2 (en) * 2010-04-28 2011-11-10 Rib-X Pharmaceuticals, Inc. Method for treating mycobacterial infections
WO2016061772A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0352781A2 (en) * 1988-07-29 1990-01-31 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
WO1993009103A1 (en) * 1991-11-01 1993-05-13 The Upjohn Company Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
WO2004029066A2 (en) * 2002-09-26 2004-04-08 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
WO2005061468A1 (en) * 2003-12-17 2005-07-07 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
WO2006133397A2 (en) * 2005-06-08 2006-12-14 Rib-X Pharmaceuticals, Inc. Process for the synthesis of triazoles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0352781A2 (en) * 1988-07-29 1990-01-31 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
WO1993009103A1 (en) * 1991-11-01 1993-05-13 The Upjohn Company Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
WO2004029066A2 (en) * 2002-09-26 2004-04-08 Rib-X Pharmaceuticals, Inc. Bifunctional heterocyclic compounds and methods of making and using same
WO2005061468A1 (en) * 2003-12-17 2005-07-07 Rib-X Pharmaceuticals, Inc. Halogenated biaryl heterocyclic compounds and methods of making and using the same
WO2006133397A2 (en) * 2005-06-08 2006-12-14 Rib-X Pharmaceuticals, Inc. Process for the synthesis of triazoles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEIDNER-WELLS M A ET AL: "The synthesis and antimicrobial evaluation of a new series of isoxazolinyl oxazolidinones", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 14, no. 12, 21 June 2004 (2004-06-21), pages 3069 - 3072, XP004841345, ISSN: 0960-894X *

Also Published As

Publication number Publication date
WO2007133803A2 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
WO2007106536A3 (en) Methods for producing an immune response to tuberculosis
WO2009109532A3 (en) Use of defensins against tuberculosis
WO2010090860A3 (en) Methods and compositions for treating bacterial infection
WO2007140002A3 (en) Method for treating non-hodgkin's lymphoma
WO2008115281A3 (en) Compounds for treating viral infections
WO2008041966A3 (en) Broad spectrum antibacterial compounds
WO2009109908A8 (en) Methods of treating inflammatory pain
WO2008153610A3 (en) Use of il-23 antagonists for treatment of infection
WO2009026166A3 (en) Antiinfective flavonol compounds and methods of use thereof
ZA200701629B (en) Gyrase inhibitors and uses thereof
WO2010015815A3 (en) Compounds for the treatment of flaviviral infections
WO2011063263A3 (en) Methods for producing an immune response to tuberculosis
WO2008005651A3 (en) Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis
EP4143235A4 (en) Methods and compositions for treating cytokine storm infections, including covid-19, by inhibiting ccr5/ccl5 interaction
WO2009085277A3 (en) Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
WO2010065735A3 (en) Methods and compositions for treating p.acnes
WO2006063176A3 (en) Inhibition of biofilm formation using bacteriophage
WO2008133734A3 (en) Method and compositions for treating hiv infections
WO2010032011A3 (en) Anti-fungal therapy
WO2012103295A3 (en) Small molecule rnase inhibitors and methods of use
WO2007089612A3 (en) Methods and compositions for treating and preventing bacterial infections
IN2012DN01414A (en)
WO2010134827A9 (en) Extended acting oxygen generating composition for treating microbial infections
WO2015126930A3 (en) Booster drug therapy for mycobacterium infections
EP3939599A3 (en) Silicate containing compositions and methods of treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07794930

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07794930

Country of ref document: EP

Kind code of ref document: A2